![]() |
市場調查報告書
商品編碼
2026901
Western Blotting市場預測至2034年-按產品、應用、最終用戶和地區分類的全球分析Western Blotting Market Forecasts to 2034 - Global Analysis By Product (Consumables, Instruments and Other Products), Application (Clinical Diagnostics, Food & Beverages and Other Applications), End User and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球蛋白質印跡市場規模將達到 15.2 億美元,並在預測期內以 8.7% 的複合年成長率成長,到 2034 年將達到 29.5 億美元。
蛋白質分析和檢測是分子生物學技術-蛋白質印跡法(Western blotting)的常見應用。此方法首先利用凝膠電泳將蛋白質依大小分離,然後將分離的蛋白質轉移到膜上。蛋白質印跡法廣泛應用於眾多科學領域,用於研究蛋白質表現、轉譯後修飾和相互作用。
根據美國疾病管制與預防中心(CDC)公佈的數據,2020 年美國有 30635 人被診斷出感染 HIV。
對生物醫學研究的需求日益成長
蛋白質印跡法極大地促進了細胞過程、蛋白質表現和相互作用的研究,為神經生物學和腫瘤學等領域帶來了重要的全新見解。隨著生物醫學研究領域的拓展和對精確蛋白質分析需求的日益成長,蛋白質印跡法已成為不可或缺的工具。此外,其在闡明疾病、理解分子機制和檢驗研究結果方面的多功能性,西方印漬術成為一項基礎性工具,並透過滿足生物醫學研究界不斷變化的需求,推動了該市場的發展和創新。
前期成本高
Western blotting 的成本主要來自多個方面,包括使用昂貴的試劑和耗材,例如封閉劑、檢測基材和抗體。成像設備和凝膠電泳系統等專用設備也會增加總成本。此外,對熟練操作人員的需求也進一步推高了這項技術的成本。高昂的檢測成本是限制市場成長的一大障礙。
政府措施和支持
美國國立衛生研究院 (NIH) 等政府機構正在資助利用蛋白質印跡技術進行的計畫。這種支持正在加速創新、技術進步以及生物醫學、藥物研發和診斷等領域新應用的研究。此外,這種資金支持正在為蛋白質分析及相關研究的發展創造有利環境,透過改善技術應用,加速科學發現並促進市場擴張。
缺乏標準化
不同實驗室間操作流程、試劑和設備的不相容性會阻礙結果的重複性。調查方法的差異會影響數據的可靠性,使研究人員難以比較和檢驗研究結果。標準化問題會影響蛋白質印跡法的評估,引發人們對數據準確性的質疑,並使研究團隊之間的合作更具挑戰性。
新型冠狀病毒(COVID-19)的影響
供應鏈中斷、物流挑戰以及實驗室活動限制阻礙了蛋白質印跡試劑和設備的生產和分銷。封鎖措施導致許多研究項目延期或暫停,進而影響了對這些產品的需求。此外,非新冠肺炎相關研究經費的減少也限制了可用於蛋白質印跡研究的資源。最終,研究重點轉向新冠肺炎導致其他領域的關注和資源被轉移。經濟的不確定性加劇了人們對成本的擔憂,進而影響了科學界的採購決策。
在預測期內,設備細分市場預計將是規模最大的。
由於其在分子生物學和蛋白質研究中發揮著至關重要的作用,儀器設備領域預計將佔據最大的市場佔有率。這些儀器在從複雜的生物樣本中精確分離、轉錄和檢測蛋白質方面發揮關鍵作用。製造商不斷創新,透過整合高速電泳、半乾式或濕式轉錄功能以及先進的成像技術等特性,為研究人員提供最先進的系統。此外,這些儀器還包括用於根據大小分離蛋白質的電泳系統、用於轉移蛋白質的轉錄系統以及用於可視化和定量蛋白質條帶的成像系統,這些都推動了該領域的擴張。
預計在預測期內,生物製藥和生技公司板塊的複合年成長率將最高。
由於這些儀器在藥物研發、品管和研究方法中的蛋白質分析應用廣泛,因此預計生物製藥和生物技術公司板塊在預測期內將呈現最高的複合年成長率。此技術有助於評估蛋白質表現、檢驗治療標靶並確保產品一致性。此外,它透過提供精準的蛋白質表徵訊息,推動生物製藥開發和生物技術研究的進步。該板塊是生物製藥開發和生產的關鍵相關人員群體,因此也是推動其成長的主要動力。
在預測期內,北美佔據了最大的市場佔有率,這主要得益於政府對生物技術和醫療保健領域研發的支持項目。學術機構、研究組織和產業相關人員之間的合作正在推動創新和應用。此外,這些合作如今已符合美國食品藥物管理局(FDA) 等機構制定的法規結構所設定的品質標準,確保了研究和診斷的可靠性,從而擴大了該地區的市場規模。
預計在預測期內,歐洲將錄得最高的複合年成長率,這主要得益於生命科學研究中檢測技術、轉錄策略和凝膠電泳系統的進步。這些方法如今更加精準高效,而歐洲促進研發的政策以及支持生物技術和醫療保健創新的舉措進一步推動了這一成長。博斯特生物技術公司、通用電氣醫療集團、珀金埃爾默公司和丹納赫公司等領先企業為該地區嚴格的監管政策和品質標準的建立做出了貢獻,這些政策和標準正在推動該地區的成長。
According to Stratistics MRC, the Global Western Blotting Market is accounted for $1.52 billion in 2026 and is expected to reach $2.95 billion by 2034 growing at a CAGR of 8.7% during the forecast period. Protein analysis and detection are common applications of the molecular biology technique known as western blotting. It involves transferring the separated proteins onto a membrane after they have been separated by size using gel electrophoresis. Numerous scientific domains utilize western blotting to aid in the investigation of protein expression, post-translational modifications, and interactions.
According to data published by the Centers for Disease Control and Prevention (CDC), stated that in 2020, 30,635 people received an HIV diagnosis in the U.S.
Increase in biomedical research demand
The study of cellular processes, protein expression, and interactions is greatly aided by western blotting, which provides important new understandings in fields like neurobiology and cancer. It is essential as the field of biomedical research grows and the need for precise protein analysis increases. Furthermore, its versatility in exploring diseases, understanding molecular mechanisms, and validating research findings positions it as a fundamental tool, to meet the evolving demands of the biomedical research community which is driving adoption and innovation of this market's growth.
High initial cost
The cost of Western blotting can be attributed to several reasons, such as the fact that the procedure necessitates the use of costly reagents and consumables, including blocking agents, detection substrates, and antibodies. Specialized tools like imaging equipment and gel electrophoresis systems also raise the overall cost. Furthermore, the cost of using the technique is further increased by the requirement for skilled personnel. The high expense of carrying out these tests is one significant obstacle to the market.
Government initiatives and support
Initiatives from government bodies, such as the National Institutes of Health (NIH), allocate funds to projects involving Western blotting techniques. Innovation, technical progress, and the investigation of novel uses in biomedicine, medication development, and diagnostics are all encouraged by this support. Furthermore, the financial support creates a favorable environment for developments in protein analysis and related research, speeds up scientific discoveries, and supports by improving accessibility which is driving this market expansion.
Lack of standardization
Incompatibilities across laboratories in procedures, reagents, and equipment hinder result reproducibility. Variability in methodologies impacts data reliability, making it challenging for researchers to compare and validate findings. Problems with standardization can damage Western blotting's image, raising doubts regarding the accuracy of the data and making it more difficult for research groups to collaborate.
Covid-19 Impact
Disruptions in supply chains, logistical challenges, and restrictions on laboratory activities have hindered the production and distribution of Western blotting reagents and instruments. Many research projects were delayed or halted due to lockdowns, impacting the demand for these products. Furthermore, the resources available for Western blotting studies have been restricted due to decreased funding for research irrelevant to COVID-19. Eventually, attention and resources have been diverted from other areas due to the shift in research priorities towards COVID-19. Economic uncertainties have prompted cost-consciousness, affecting purchasing decisions in the scientific community.
The instruments segment is expected to be the largest during the forecast period
The instrument segment is estimated to hold the largest share due to its crucial role in molecular biology and protein research. They play a pivotal role in the precise separation, transfer, and detection of proteins from complex biological samples. Manufacturers continually innovate to provide researchers with state-of-the-art systems, incorporating features like rapid electrophoresis, semi-dry or wet transfer capabilities, and advanced imaging technologies. Furthermore, these instruments include electrophoresis systems for separating proteins based on size, transfer systems for transferring proteins, and imaging systems for visualizing and quantifying protein bands, which is driving this segment expansion.
The biopharmaceutical & biotechnology companies segment is expected to have the highest CAGR during the forecast period
The biopharmaceutical & biotechnology companies segment is anticipated to have highest CAGR during the forecast period due to the use of these companies for protein analysis in drug development, quality control, and research processes. The technique aids in assessing protein expression, validating therapeutic targets, and ensuring product consistency. Additionally, by providing precise insights into protein characteristics, it supports the development of biopharmaceuticals and the advancement of biotechnological research. It represents a key stakeholder group in the development and production of biotherapeutics, thereby boosting this segment's growth.
North America commanded the largest market share during the extrapolated period owing to government programs that support scientific research and development, especially in the biotechnology and healthcare sectors. Collaborations between academic institutions, research organizations, and industry players foster innovation and applications. Furthermore, these now meet quality standards set by regulatory frameworks established by organizations such as the Food and Drug Administration (FDA), guaranteeing dependability in research and diagnostics, thereby propelling this region's size.
Europe is expected to witness highest CAGR over the projection period due to advancements in detection technologies, transfer strategies, and gel electrophoresis systems in life sciences research. These procedures are now more accurate and efficient European policies promoting research and development, coupled with initiatives supporting biotechnology and healthcare innovation. Some of the key players including Boster Biological Technology, GE Healthcare, PerkinElmer Inc. and Danaher Corporation contribute to strict regulatory policies and quality standards which are driving this region's growth.
Key players in the market
Some of the key players in the Western Blotting Market include Abcam Plc, Advansta, Inc., Azure biosystems, inc., Bio-Techne Corporation, Boster Biological Technology, Cell signaling technology, inc., Danaher Corporation, EMD Millipore Corporation, GE Healthcare, Hofmann-La Roche Ltd., LI-COR, Inc., Merck Kgaa, PerkinElmer Inc., Stressmarq biosciences inc. and Thermo Fisher Scientific, Inc.
In November 2023, GE HealthCare and Masimo announced a joint agreement to integrate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution.
In October 2023, Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash.
In October 2023, GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase. As clinicians work to treat CVD, cardiology procedures continue to evolve as demand for minimally invasive surgery grows.